CLINICAL AND LABORATORY STANDARDS INSTITUTE®

2nd Edition

M53

Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection

This guideline includes recommendations for performing human immunodeficiency virus testing and for interpretation of results by health care providers in advanced diagnostic laboratories.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

M53-Ed2
August 2023
Replaces M53-A

Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection

Eric S. Rosenberg, MD
Joseph D.C. Yao, MD
Ted E. Schutzbank, PhD, D(ABMM)
Neil Anderson, MD, D(ABMM)
Yap Boum, II, PhD, MRQA
Ana Maria Cardenas, PhD, D(ABMM)
Arlene Darmanie, MSc
Anne M. Gaynor, PhD
Renee M. Howell, PhD, MLS(ASCP)
Kamran Kadkhoda, PhD, F(CCM), D(ABMM), D(ABMLI), SM(ASCP)
William Link, MS, BS
S. Michele Owen, PhD
Monica M. Parker, PhD
Sai A. Patibandla, PhD
Raghava Potula, MHA, PhD
Bouchra Serhir, PhD
Charles M. Walworth, MD
Yun F. (Wayne) Wang, MD, PhD

Abstract

Clinical and Laboratory Standards Institute guideline M53—*Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection* provides an extensive review of existing laboratory methods commonly used to test for HIV infection. The accurate diagnosis of HIV infection is essential for limiting the spread of infection and for the appropriate clinical management of persons infected with HIV. Numerous tests and strategies have been developed and are used by laboratorians and clinicians to diagnose HIV infection. This guideline also offers recommendations for how to best use and interpret these tests accurately and effectively to diagnose HIV infection.

Clinical and Laboratory Standards Institute (CLSI). *Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection.* 2nd ed. CLSI guideline M53 (ISBN 978-1-68440-187-1 [Print]; ISBN 978-1-68440-188-8 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2023.

CLINICAL AND LABORATORY STANDARDS INSTITUTE®

Suggested Citation

CLSI. *Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection.* 2nd ed. CLSI guideline M53. Clinical and Laboratory Standards Institute; 2023.

Previous Edition:
June 2011

M53-Ed2
ISBN 978-1-68440-187-1 (Print)
ISBN 978-1-68440-188-8 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)
Volume 43, Number 19

Committee Membership

Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: https://clsi.org/standards-development/consensus-council/

Document Development Committee on HIV

Eric S. Rosenberg, MD
Chairholder
Massachusetts General Hospital
USA

Joseph D.C. Yao, MD
Vice-Chairholder
Mayo Clinic
USA

Ted E. Schutzbank, PhD, D(ABMM)
Committee Secretary
Agena Bioscience
USA

Neil Anderson, MD, D(ABMM)
College of American Pathologists
USA

Yap Boum, II, PhD, MRQA
Epicentre/Medecins Sans Frontieres
Uganda

Ana Maria Cardenas, PhD, D(ABMM)
Becton Dickinson
USA

Arlene Darmanie, MSc
Trinidad and Tobago

Renee M. Howell, PhD, MLS(ASCP)
Siemens Healthineers
USA

Kamran Kadkhoda, PhD, F(CCM), D(ABMM), D(ABMLI), SM(ASCP)
Cleveland Clinic
USA

William Link, MS, BS
Bio-Rad Laboratories
USA

S. Michele Owen, PhD
Centers for Disease Control and Prevention
USA

Monica M. Parker, PhD
Wadsworth Center, New York State Department of Health
USA

Yun F. (Wayne) Wang, MD, PhD
Grady Memorial Hospital/
Emory University School of Medicine
USA

Expert Panel on Microbiology

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: https://clsi.org/standards-development/expert-panels/

Staff

Clinical and Laboratory Standards Institute
USA

Christine M. Lam, MLS(ASCP)
Program Manager

DeeDee P. Meadows, MLS(ASCP)MP
Program Manager

Laura Martin
Editorial Manager

Catherine E.M. Jenkins, ELS
Editor

Kristy L. Leirer, MS
Editor

Lisa M.W. Walker, MS, ELS
Editor

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on HIV gratefully acknowledge the following volunteers for their important contributions to the revision of this guideline:

Anne M. Gaynor, PhD
Association of Public Health Laboratories
USA

Sai A. Patibandla, PhD
Siemens Healthineers
USA

Raghava Potula, MHA, PhD
Temple University Hospital
USA

Bouchra Serhir, PhD
Institut national de santé publique du Québec
Canada

Charles M. Walworth, MD
LabCorp of America
USA

Contents

Abstract i
Committee Membership iii
Foreword vii
Chapter 1: Introduction 1
1.1 Scope 1
1.2 Background 3
1.3 Standard Precautions 8
1.4 Terminology 8
Chapter 2: HIV Testing and Interpretation Process 15
Chapter 3: Tests for Diagnosing HIV Infection 17
3.1 Laboratory Immunoassays 19
3.2 Single-Use HIV-Screening Devices 25
3.3 Molecular Assays 29
3.4 Rarely Used Assays (Available but Not Preferred or Recommended) 32
Chapter 4: Approaches for Diagnostic Testing 33
4.1 Initial and Supplemental Testing 34
4.2 *In Vitro* Diagnostic Device Modification and Laboratory-Developed Tests 39
4.3 Notification of Significant Results 39
4.4 Postexamination Specimen Retention 40
Chapter 5: Algorithms for Selecting HIV Testing Protocols 41
5.1 Recommended (Preferred) Algorithms 43
5.2 Alternative Algorithms 47
5.3 Resolving Inconclusive or Persistently Indeterminate Results 51

Contents (Continued)

Chapter 6: Special Situations for HIV Testing 53

6.1 Acute HIV Type 1 Infections 54

6.2 Determining Recent Infection to Estimate Incidence of HIV Infection 56

6.3 HIV Type 1 Group M, Non-B Subtype Infection 59

6.4 HIV Type 2 60

6.5 HIV Types 1 and 2 Combination Initial and Supplemental Testing in Pregnancy 62

6.6 Testing in Children Younger Than 24 Months of Age (Algorithm VII) 63

6.7 HIV Type 1 Seroreversion or Incomplete Anti-HIV Type 1 Antibody Response 66

6.8 HIV Experimental Vaccine or Chimeric Antigen Receptor T-Cell Therapy (Lentivirus Vector) Recipients 66

6.9 Natural Viral Nonprogressors (Elite Controllers) 67

6.10 Testing in Preexposure Prophylaxis and Postexposure Prophylaxis 68

6.11 Cerebrospinal Fluid Testing in HIV-Associated Central Nervous System Disorders 69

6.12 Self-Collection and Self-Testing 70

Chapter 7: Tests for Managing HIV Type 1 Infection 71

7.1 CD4+ T-Cell Subset Monitoring 72

7.2 Quantitative HIV Type 1 RNA Tests 72

7.3 HIV Type 1 Drug-Resistance Tests 74

Chapter 8: Quality Management System Process Management for HIV Testing 83

8.1 Establishing an HIV Testing Quality Control Program 84

8.2 HIV Control Materials 84

8.3 HIV Proficiency Testing Programs 85

8.4 Quality Control Considerations for Rapid Tests 85

Chapter 9: Conclusion 87

Chapter 10: Supplemental Information 89

References 90

Additional Resources 113

Appendix A. Rarely Used Assays (Available but Not Preferred or Recommended) 114

Appendix B. Reporting Comments Suggested for Initial and Supplemental HIV Diagnostic Test Results 126

The Quality Management System Approach 134

Foreword

Since HIV testing was introduced, laboratory-based methods have undergone tremendous change. The routine use of nucleic acid testing, the introduction of antigen/antibody combination tests, and the widespread implementation of rapid testing methods, including the use of different specimen types, have changed the way HIV infection is diagnosed. Although these tests may offer improved sensitivity, specificity, and turnaround times, clinicians and laboratorians need to determine which tests to perform and how to best interpret the results.

There is increasing momentum to establish universal routine testing programs for HIV infection to limit the spread of infection and to identify individuals who may benefit from earlier initiation of antiviral therapy. The Centers for Disease Control and Prevention has issued recommendations for routine HIV screening of all patients in the health care setting. Concurrent with these recommendations, laboratorians and clinicians have used several new tests and testing strategies to diagnose HIV infection. Although an increased demand for these tests exists, adequate consensus guidelines have not been proposed to assist in the appropriate use and interpretation of these tests and testing strategies.

Overview of Changes

This guideline replaces the previous edition of the approved guideline, M53-A, published in 2011. Several changes were made in this edition, including:

- Reorganizing the text to follow the testing path of workflow
- Expanding the scope to include testing recommendations for resource-limited settings and for managing patients with HIV type 1-positive infections
- Adding an HIV testing and interpretation process flow chart
- Revising the algorithms used to select HIV testing protocols and associated text
- Deleting all references to HIV test "generations"
- Updating:
  - Information on currently available and discontinued HIV tests
  - Test principal figures
  - Information on molecular testing
  - Recommended approaches for HIV diagnostic testing
  - Special situations for HIV testing
  - QC information

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

algorithms
antibody differentiation assay
antibody discrimination assay
enzyme immunoassay
genotypic drug-resistance test
HIV-1
HIV-2
immunoassay
initial test
nucleic acid test
phenotypic drug-resistance test
single-use devices
supplemental test
Western blot

Chapter 1

Introduction